Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

NCT02646735 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant 500 mg
DRUG: Exemestane 25 mg

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]